Partnering with Pharmaron for successful XDC discovery and development means working with a team that supports every stage of the process.
From early discovery through to development and manufacturing, Pharmaron provides true end-to-end XDC expertise. Its strong chemistry capabilities help enable the design of well-engineered XDCs, while robust efficacy models support smarter, more confident candidate selection.
With development and manufacturing brought together in one place, teams can move more efficiently, streamline collaboration, and keep programs progressing smoothly from concept to production.
- Antibody and payload screening and synthesis
- Bioconjugation and GMP production
- Conducting biology and efficacy testing
- Safety and DMPK assessment
Pharmaron’s goal of a true end-to-end XDC platform
Pharmaron offers a full portfolio for XDC discovery, development, and production. With over 1200 ADCs and alternative conjugates successfully provided to date, Pharmaron enables its partners to move confidently toward stable, powerful, and safe therapeutic prospects.
Pharmaron’s knowledge includes a wide range of current conjugation options:
- XDC Formats: ADC (antibody-drug conjugate), PDX (peptidedrug conjugate), AOC (antibody-oligo conjugate)
- Targeting Formats: mAbs, bsAbs, Fab fragments, nanobodies, peptides, proteins
- Linkers: Cleavable and non-cleavable, enzymatic, pH-sensitive, reducible
- Payloads: Cytotoxics, immune modulators, degraders, oligonucleotides, and more
Why Pharmaron?
With all key disciplines integrated under one roof, Pharmaron helps streamline the drug discovery and development process. This integrated approach reduces handoffs, minimizes the risk of data loss between phases, and supports faster, more informed decision-making as programs progress from early ideas to preclinical and clinical candidates.
Pharmaron supports drug discovery teams at every stage, whether they need a single specialized assay, support for compound optimization campaigns, GMP manufacturing for clinical trial supplies, or fully integrated discovery-to-IND programs.
About Pharmaron
Pharmaron is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.